Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation
作者:Carlos Jaramillo、J. Eugenio de Diego、Chafiq Hamdouchi、Elizabeth Collins、Heather Keyser、Concha Sánchez-Martı́nez、Miriam del Prado、Bryan Norman、Harold B. Brooks、Scott A. Watkins、Charles D. Spencer、Jack Alan Dempsey、Bryan D. Anderson、Robert M. Campbell、Tellie Leggett、Bharvin Patel、Richard M. Schultz、Juan Espinosa、Michal Vieth、Faming Zhang、David E. Timm
DOI:10.1016/j.bmcl.2004.09.053
日期:2004.12
We have identified a novel structural class of protein serine/threonine kinase inhibitors comprised of an aminoimidazo[1,2-a]pyridine nucleus. Compounds from this family are shown to potently inhibit cyclin-dependent kinases by competing with ATP for binding to a catalytic subunit of the protein. Structure-based design approach was used to direct this chemical scaffold toward generating potent and
我们已经确定了由氨基咪唑并[1,2-a]吡啶核组成的蛋白质丝氨酸/苏氨酸激酶抑制剂的新型结构类别。已显示该家族化合物通过与ATP竞争结合蛋白的催化亚基而有效抑制细胞周期蛋白依赖性激酶。基于结构的设计方法用于指导该化学支架产生有效的和选择性的CDK2抑制剂。这类新型的ATP定位的蛋白激酶抑制剂氨基咪唑并[1,2-a]吡啶类化合物的发现,为寻求有效治疗癌症和其他涉及蛋白激酶信号传导途径的疾病的药物化学工具提供了基础。